Abeona Therapeutics (ABEO) Non-Current Deffered Revenue (2010 - 2026)

Abeona Therapeutics' (ABEO) quarterly Non-Current Deffered Revenue came in at $425000.0 in Q1 2026, down 86.12% quarter-over-quarter from $3.1 million in Q4 2017.

Abeona Therapeutics (ABEO) Non-Current Deffered Revenue (2010 - 2026) Analysis & Trends

Abeona Therapeutics' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $425000.0 for Q1 2026.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $425000.0 in Q1 2026; TTM through Mar 2026 was $425000.0, a N/A change from a year earlier, with the FY2017 full-year figure at $3.1 million, down 16.46% from the prior year.
  • Non-Current Deffered Revenue declined to $425000.0 in Q1 2026 per ABEO's latest filing, from $3.1 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $425000.0 in Q1 2026 and bottomed at $425000.0 in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 225.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Abeona Therapeutics 107.85 Mn -60.42 Mn 6.02 Mn 425,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 425,000.00
Dec 31, 2017 3.06 Mn
Sep 30, 2017 3.21 Mn
Jun 30, 2017 3.36 Mn
Mar 31, 2017 3.51 Mn
Dec 31, 2016 3.66 Mn
Sep 30, 2016 3.81 Mn
Jun 30, 2016 3.97 Mn
Mar 31, 2016 4.12 Mn
Dec 31, 2015 4.27 Mn
Sep 30, 2015 4.42 Mn
Jun 30, 2015 4.57 Mn
Mar 31, 2015 4.72 Mn
Dec 31, 2014 4.87 Mn
Sep 30, 2014 5.02 Mn
Jun 30, 2014 5.17 Mn
Mar 31, 2014 5.32 Mn
Dec 31, 2013 5.24 Mn
Sep 30, 2013 5.39 Mn
Jun 30, 2013 5.53 Mn